米国FDA/COVID-19絡みのガイダンス等の発出と更新(2021年4月9日付)
4/9付の米国FDAによるCOVID-19絡みガイダンス等の発出について、筆者のお好みでお伝えします。
関係者および興味のある方は、下記URLsの更新通知等をご参照ください。
l4/9付News Release「Coronavirus (COVID-19) Update: April 9, 2021」
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-april-9-2021
l4/9付New「CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19」
https://www.fda.gov/drugs/coronavirus-covid-19-drugs/cder-scientific-review-documents-supporting-emergency-use-authorizations-drug-and-biological
l4/9付Updated「Notifications and Emergency Use Authorizations: FAQs on Testing for SARS-CoV-2」
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/notifications-and-emergency-use-authorizations-faqs-testing-sars-cov-2
l4/9付Updated「Removal Lists of Tests that Should No Longer Be Used and/or Distributed for COVID-19: FAQs on Testing for SARS-CoV-2」
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/removal-lists-tests-should-no-longer-be-used-andor-distributed-covid-19-faqs-testing-sars-cov-2
[FDA全体に関するニュース記事]
l4/9付RAPS「Woodcock: Post-COVID, new flexibility could boost cancer trial diversity」
https://www.raps.org/news-and-articles/news-articles/2021/4/woodcock-post-covid-new-flexibility-could-boost-ca
関係者および興味のある方は、下記URLsの更新通知等をご参照
l4/9付News Release「Coronavirus (COVID-19) Update: April 9, 2021」
https://www.fda.gov/news-
l4/9付New「CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19」
https://www.fda.gov/drugs/
l4/9付Updated「Notifications and Emergency Use Authorizations: FAQs on Testing for SARS-CoV-2」
https://www.fda.gov/medical-
l4/9付Updated「Removal Lists of Tests that Should No Longer Be Used and/or Distributed for COVID-19: FAQs on Testing for SARS-CoV-2」
https://www.fda.gov/medical-
[FDA全体に関するニュース記事]
l4/9付RAPS「Woodcock: Post-COVID, new flexibility could boost cancer trial diversity」
https://www.raps.org/news-and-
コメント
/
/
/
コメント